Disclosures: Shunsuke Ikejima: Nothing to Disclose, Kazuyoshi Kon: Nothing to Disclose, Kumiko Arai: Nothing to Disclose, Akira Uchiyama: Nothing to Disclose, Hiroo Fukada: Nothing to Disclose, Kyoko Fukuhara: Nothing to Disclose, Reiko Yaginuma: Nothing to Disclose, Maki Morinaga: Nothing to Disclose, Masahiro Tada: Nothing to Disclose, SHUNHEI YAMASHINA: Nothing to Disclose, Kenichi Ikejima: Nothing to Disclose 627 FIBROBLAST GROWTH FACTOR 15/19 (FGF15/19) REGULATES CIRCADIAN ENERGY METABOLISM IN SHIFT WORKERS Zhenning Yang 1 Bo Kong 1 Mingzhu Fang 2 Rulaiha Taylor 1 Helmut Zarbl 1 Grace Guo 1 , 1 Rutgers University, 2 Bristol Myers Squibb Background: Chronic disruption of circadian rhythm by shift work is an important risk factor for metabolic diseases
Outliers detected in MR-PRESSO for overall and sex-specific associations of genetically predicted l-carnitine with CVD and CVD risk factors
Injections deliver vitamins directly into the bloodstream, ensuring maximum absorption and faster results
the composition comprises at least about 0.005 %, at least about 0.01 %, at least about 0.05 %, at least about 0.1 %, at least about 0.2 %, at least about 0.3 %, at least about 0.4 %, at least about 0.5 %, at least about 0.6 %, at least about 0.7 %, at least about 0.8 %, at least about 0.9 %, at least about 1.0 %, at least about 1.1 %, at least about 1.2 %, at least about 1.3 %, at least about 1.4 %, at least about 1.5 %, at least about 1.6 %, at least about 1.7 %, at least about 1.8 %, at least about 1.9 %, at least about 2.0 %, at least about 2.1 %, at least about 2.2 %, at least about 2.3 %, at least about 2.4 %, at least about 2.5 %, at least about 2.6 %, at least about 2.7 %, at least about 2.8 compositions provided herein comprise at least about 1.5 % anti-acne ingredient (e.g., salicylic acid) by weight of the composition
Some of the lesions had developed superficial vesicles (Fig
